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Five-year survival of patients with advanced melanoma 
is estimated to be 6%. Partial responses were observed 
only for 10% of patients with advanced melanoma treated 
with cisplatinum. Radiotherapy and chemotherapy are 
inefficient, due to radioprotective and antioxidant prop-
erties of melanines. Immunotherapy, gene-therapy and 
other forms of chemotherapy are promising, but still not 
satisfactory [1, 2]. Therefore much attention has been 
paid on design of new platinum compounds with improved 
pharmacological properties against melanoma cells [3]. 
Consequently new platinum drugs with equal or better 
antitumor activity but less toxicity have been developed by 
modifying the pharmacokinetics of cisplatin, replacing the 
chloride labile and stable amine ligands with other leaving 
groups. Another way to design new anti-tumor pro-drugs 
related to cisplatin is to change the nature of the central 
ion and used a six-coordinate octahedral platinum(IV) 
derivatives. Several platinum(IV) complexes are showing 
considerable promise in initial trials, with functionality 
thought to depend on the in vivo reduction of Pt(IV) to 
Pt(II), producing reactive intermediates that then interact 
with DNA. In our previous study we found that PtCl4(dmtp)2 
had a good cytotoxic properties, but the solubility was still 
low [4, 5]. Therefore intention of our research was to test a 
new platinum(IV) compounds with difference heterocycle 
ligands which reveal better solubility. For our study we 
choose PtCl4(dbtp)2 (Fig. 1, a), with bulky tertbutyl group. 
Probably presence of the tertbutyl in heterocyle ligands 
is a key to interaction of the platinum complexes with 
cellular components. In addition, our earlier study show 
that the platinum(II) and platinum(IV) presented high 
antitumor activity against human tumour cells (SW707 
rectal adenocarcinoma, T47D breast cancer and HCV29T 
bladder cancer). In this paper we present in vitro cytotoxic 
effect of two new platinum(IV) complexes; PtCl4(dbtp)2 
and PtCl2(6mp)2 (Fig. 1, b) against B16 mouse melanoma 
cells. Apoptotic response as a strong predictor for drug 
effectiveness against neoplasmatic cells was examined as 
well. Cell cycle was analyzed additionally, to find, if there 
are specific disturbances of the cell cycle.
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Fig. 1. Schematic molecular representation of PtCl4(dbtp)2 (a) 
and PtCl2(6mp)2 (b)
Compounds able to trigger apoptosis within target 
cells are effective anticancer drugs. Cells resistant to 
chemotherapy are often characterized by the lack of 
apoptotic response during systemic treatment. Apop-
tosis can be evoked during the whole cell cycle, but the 
most suspicious are check points G1/S and G2/M [6].
MATERIAL AND METHODS
Preparation of platinum(IV) complexes. PtCl4(dbtp)2 
was obtained by reaction of H2PtCl6 with dbtp in molar ratio 
M : L=1 : 2 [7]. PtCl2(6-mp)2 was obtained by the reaction 
of 330 µl (0.1 mmol) of H2PtCl6, dissolved in 25 cm
3 of 2 M 
HCl, with 0.340 g (2 mmol) of 6-Hmp ⋅ H2O in 25 cm
3 of 
methanol. The reaction mixture was heated to 60 °C and 
stirred for 3 h. The yellow precipitate was filtered, washed 
with methanol, diethyl ether and dried in vacuum.
Mouse Melanoma B16 cell line. B16 cells were prop-
agated from tumor localized in peritoneum of C57Bl/6J 
mouse. Cells were cultivated in complete DMEM (Sigma) 
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medium supplemented with 10% fetal bovine serum 
(Sigma, USA) and antibiotics as previously described [8].
Cytotoxicity studies. 24-well plates (Nunc, USA) 
were used in cytotoxic studies. B16 cells were seeded 
in each well in amount of 105 and covered with fresh 
culture medium for 24 h. Then culture medium was 
removed and tested platinum compounds were added 
in appropriate concentrations, dissolved in 0.1% DMSO. 
Each solution was prepared immediately before use. 
Cells were incubated with platinum complexes for 6 h. 
Then cultures were rinsed with PBS and cells were de-
tached with 0.05% trypsin. Cells were centrifuged 5 min 
at 900 g. Cells in suspensions were stained with trypan 
blue and counted in Neubauer chamber under magnifi-
cation of 100 X. Cytotoxicity of tested compounds was 
calculated as the number of viable B16 cells in relation 
to control. Our previous study proved that 0.1% DMSO 
does not affect on viability of B16 cells. Melanoma cells 
viability was estimated using the regression curves. Re-
gression curves equations were used to calculate LC10, 
LC50, LC90 (lethal concentration) values. Correlation 
coefficients were calculated and checked by Pearson 
test. p < 0.05 was statistically significant.
Apoptosis and necrosis detection using flow 
cytometry. To detect apoptotic and necrotic cells 
Annexin V conjugated with fluorescein izothiocyanate 
(Annexin V-FITC, Immunotech) and propidium iodide 
(PI), (Immunotech, USA) were used [5]. Melanoma cells 
were cultured in 50 mm diameter Petri dishes. Each 
dish contained 105 cells in 5 ml of medium. Platinum 
complexes were added to each culture after 24 h prein-
cubation. Apoptotic B16 cells were counted after 6 h and 
12 h incubation with both complexes. Cells incubated 
with PBS were used as control samples. 105 of B16 cells 
were suspended in 0.5 ml of binding buffer containing 
Annexin V-FITC and propidium iodide (Immunotech). 
Then probes were shaken 5 s in automatic stirrer (Coulter, 
Miami, FL, USA), and incubated 10 min in darkness at 
4 °C. Analysis was performed using flow cytometr EPICS 
XL (Coulter) with System 2 Software Version 1.0. Three 
separate measurements were done for each experiment. 
Resulted were presented as mean +/– standard deviation 
(SD). The probability between differences of means in 
groups of apoptotic cells was evaluated with t-Student 
test. p < 0.05 was statistically significant.
Cell cycle analysis. DNA content and the phase 
of cell cycle was measured after staining with PI. The 
procedure was done after permeabilization of the cell 
membranes. B16 cells were incubated with platinum 
complexes. Control cells were incubated only with PBS. 
After 6, 12, 24 or 48 h incubation with tested platinum 
complexes the medium was removed and the cells (105) 
were suspended in 0.1 ml of PBS. 0.05 ml of cell suspen-
sion was transferred to the test-tube containing 0.05 ml 
of cell membrane permeabilizing agent DNA-prep LPR 
(Immunotech). Tubes were put in automatic stirrer for 8 s. 
Then 1.0 ml of DNA staining reagent (DNA-prep Stain, 
Immunotech) was added to each probe. The tubes were 
stirred again and left for 20 min in room temperature 
and darkness. Analysis was performed in EPICX XL flow 
cytometr, programmed by MultiCycle software (Phoe-
nix Flow System Inc., San Diego, CA, USA). Each value 
represents the mean from the three determinations. Re-
sulted were presented as means with standard deviations 
(SD). Comparative analysis was performed.
RESULTS
Cytotoxicity activity of PtCl4(dbtp)2 and PtCl2(6mp)2. 
Experimental cytotoxic concentrations of PtCl4(dbtp)2 
ranged from 1.2 to 124.8 µM. B16 cells viability curve after 
6 h incubation with PtCl4(dbtp)2 was presented on Fig. 2, a. 
Toxic concentration for 10% of cells (LC10) was established 
as 2.6 µM. LC50 and LC90 were 17.0 and 58.0 µM, respec-
tively (see Fig. 2, a). Experimental cytotoxic concentrations 
of PtCl2(6mp)2 were in the range 1.2–175.3 µM. LC10 and 
LC50 were 1.2 and 14.0 µM, respectively (Fig. 2, b). It was 
impossible to reach LC90 value in experimental conditions, 
due to low solubility of PtCl2(6mp)2, and precipitation of this 
compound in concentrations above 180.0 µM, hence LC90 
was only a calculated value. LC90 and for PtCl2(6mp)2 was 
6 much higher the LC90 for PtCl4(dbtp)2.
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Fig. 2. Regression curves presenting B16 cells viability after 6 h 
of incubation with PtCl4(dbtp)2 (a) and PtCl2(6mp)2 (b)
Influence of PtCl4(dbtp)2 and PtCl2(6mp)2 on 
apoptosis in B16 cells. Percentage of B16 apoptotic 
cells after 6 h and 12 h incubations with PtCl4(dbtp)2 is 
shown on Fig. 3, a. High correlation was found between 
percentage of apoptotic cells and PtCl4(dbtp)2 concen-
trations. Correlation coefficients for 6 and 12 h incubation 
times were r = 0.97 (p < 0.05) and r = 0.99 (p < 0.01), 
respectively. 25% of cells were found to be in early stages 
of apoptosis in concentration corresponding to LC50. High 
negative correlations were found between viable cells 
and concentrations during 6 h and 12 h assays, r = –0.96 
(p < 0.05) and r = –0.99 (p < 0.02).
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Fig. 3. Percentage of the apoptotic cells after exposure to 
PtCl4(dbtp)2 (a) and on PtCl2(6mp)2 (b)
Due to low solubility, only LC10 and LC50 of 
PtCl2(6mp)2 were taken for apoptosis assay. Percenta-
ge of B16 apoptotic cells after 6 and 12 h incubations 
with PtCl2(6mp)2 is shown on Fig. 3, b. High correlation 
was found between percent of apoptotic cells and 
PtCl2(6mp)2 concentrations. Correlation coefficients 
for 6 and 12 h incubation times were r = 0.99 (p < 0.01) 
and r = 0.73 (p < 0.05), respectively. High negative cor-
relations were estimated for viable cells after 6 h and 
12 h, r = –0.99 (p < 0.01) and r = –0.96 (p < 0.05).
Influence of PtCl4(dbtp)2 and PtCl2(6mp)2 on cell 
cycle in B16 cells. Cell cycle phases of B16 cells after 6, 12 
and 24 h incubation times with PtCl4(dbtp)2 are presented 
on Fig. 4, a. It was impossible to perform analysis after 48 h, 
due to small number of living cells. Cell number in G0/G1 
correlated with PtCl4(dbtp)2 concentrations in 12 and 24 h 
assays, r = –0.55 and r = –0.70, respectively. Similar corre-
lations were found for S phase (r = 0.5; r = 0.6). Inhibition of 
S-phase was observed after incubation with PtCl4(dbtp)2.
Cell cycle phases of B16 cells after 6, 12, 24 and 
48 h incubation times with PtCl2(6mp)2 are presented on 
Fig. 4, b. An accumulation of cells was observed within 
the G0/G1 phase after 12, 24 and 48 h of incubation with 
PtCl2(6mp)2. Cell number in G0/G1 phase was highly 
correlated with concentrations in 24 and 48 h assays, 
r = 0.98 (p < 0.05) and r = 0.98 (p < 0.05), respectively. Cell 
number decreased in B16 cultures after 12, 24 and 48 h 
exposition to PtCl2(6mp)2 (r = –0.87; r = –0.86; r = –0.97, 
p < 0.05). The increa sing cell number in G2/M after 12, 
24 and 48 h incubation was observed. Strong correla-
tions were noticed between cell number in G2/M phases 
and PtCl2(6mp)2 concentrations for 12 and 48 h, r = 0.98 
(p < 0.02) and r = 0.90 (p < 0.05), respectively, while after 
24 h only weak correlation was measured (r = 0.66).
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Fig. 4. Cell cycle phases in B16 cells after exposition on 
PtCl4(dbtp)2 (a) and on PtCl2(6mp)2 (b)
DISCUSSION
During the last decade the development new platinum 
drugs could be observed. These drugs which contained 
amino ligands belong to the third generation of cisplatinum 
derivates which derived from cisplatinum. The advantages 
of the platinum(IV) complexes is that they some of them 
can be used as oral drugs. This is the reason for testing 
activity of those compounds against cancer [9].
Cisplatinum belongs to alkylating agents, its antican-
cer action is connected with forming adducts between 
platinum and DNA strands. Cisplatinum also binds to 
cytoplasmatic proteins. Adducts are responsible for cell 
cycle arrest and apoptotic response. Cytotoxic effect is 
usually connected with these two phenomena [5]. Co-
valent bindings between platinum complexes and DNA 
decrease rate of replication, trans cription and following 
translation. Inhibiting the cell cycle is connected with 
excessive repair proces ses. N7 positions of guanine and 
adenine are the main binding places for platinum [10]. 
DNA can be additiona lly destroyed in secondary process 
by free radicals, which are also responsible for apoptosis 
induction after treatment with platinum compounds [8, 11]. 
Apoptosis is one of the most important processes respon-
sible for resistance during cancer chemotherapy [12].
PtCl4(dbtp)4 stopped the B16 growth in vitro. The 
both complexes partially block cell divisions and trig-
gers apoptotic cascade within tested cells.
PtCl4(dbtp)2 could be dissolved easily in DMSO while 
PtCl2(6mp)2 could not. Probably the good solubili ty of 
PtCl4(dbtp)2 was partially responsible for better cy-
totoxic effect, because higher availability of platinum 
containing molecules. The solubility was the reason of 
not achieving LC90 for PtCl2(6mp)2. PtCl4(dbtp)2 complex 
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was prepared on the basis of PtCl4(dmtp)2, a compound  
which was previously tested against B16 and ClS91 
cells. In our previous study toxicity against B16 line 
was high, but the solubility was low [5]. In current study 
four CH3 — ligands to the PtCl4(dmtp)2 were added and 
this complex reached better solubili ty while preserving 
good cytotoxic pro perties. LC50 for PtCl4(dbtp)2 and 
PtCl4(dmtp)2 were 17.0 and 0.13 µmol/l, respectively.
B16 cells were more resistant for PtCl2(6mp)2, what 
can be related to poor solubility of this complex in buff-
ered saline. Intrinsic or acquired resistance to cisplatinum 
are the main drawbacks in cancer mana gement with 
cisplatinum regimens [1, 13].
Cytotoxic properties of PtCl4(dbtp)2 and PtCl2(6mp)2 
are related to heterocyclic ligand (imidazole N-Pt bonded), 
which is recognized as a donors for hydrogen binding. The 
general scheme of many anticancer platinum complexes 
can be presented as cis-[PtX2(NHR2)2], where R is an or-
ganic ligand, X — leaving group, i. e. chloride dicarboxylic 
ions. PtCl4(dbtp)2 has a chloride ions and pyrimidine, while 
PtCl2(6mp)2 has a 6-mercaptopurine instead of pyrimidine.
When analyzing these two complexes it was obvious 
that PtCl4(dbtp)2 was more potent to induce apoptosis 
within melanoma cells than PtCl2(6mp)2. The both of 
tested complexes were able to trigger apoptosis with B16 
cells even after 6 h. Many of drugs which induce apop-
tosis are related on p53 protein and block cell cycle be-
tween G1 and S phases [14]. It seems that PtCl2(6mp)2) 
acts in similar manner. On the other hand, PtCl4(dbtp)2 
caused inhibition in S phase. This observation can be 
connected with extensive DNA destruction, which was 
not possible to repair by the cellular system. We suggest 
that apoptosis was evoked in cells which were stopped in 
G0/G1 or G2/M check points. Similar observations were 
made by Bergamo et al., (1999) who tested cisplatinum 
on Lewis and pulmonary cell cancer lines.
The most of designed cytotoxic drugs were able 
to interact with DNA strands which leaded to destroy 
of information saved in nucleic acid and in the conse-
quence cell death [15, 16]. There are many mecha-
nisms responsible for development of resistance 
during chemotherapy. One of them is lack of apoptotic 
response following systemic treatment [17, 18, 19].
In conclusion, PtCl4(dbtp)2 express higher cytotoxic 
against B16 cells than PtCl2(6mp)2. Apoptosis was the 
main mechanism of cell loss in cultures during incubation 
with the both tested complexes. PtCl4(dbtp)2 leaded to 
accumulation in S phase, while PtCl2(6mp)2 in G1/G0.
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